Almirall and Microsoft Join Forces to Develop Treatments for Skin Diseases

The Spanish multinational company Almirall, focused on dermatological treatments, announced a collaboration with the software giant Microsoft to promote innovation towards medical solutions to skin diseases. This alliance will result in the opening of a joint digital office from which the pharmaceutical company’s data platform will be improved and new compounds will be developed using generative artificial intelligence (AI) techniques.

This agreement will, first, improve Almirall’s capabilities in terms of rapid analysis of information in large data sets to advance the discovery of synthesizable molecules. Afterwards, it will allow the creation of a technological platform based on AI with which to discover new drugs.

It is expected that once the project takes shape, a new data management model will be established with which to optimize its governance , quality processes or the management of the digital identity of users of the pharmaceutical company’s products.

If you want to read more details about the agreement between Almirall and Microsoft, download for free our companion app. The Born2Invest mobile app keeps its readers up to date with the most important business news of the day.

The current president of Almirall, Carlos Gallardo Piqué, has invested in technology companies in the health sector since 2014

Almirall, a company founded in 1944 and based in Barcelona, ​​is a multinational that had a turnover of around 878.5 million euros in 2022 and has 1,800 employees around the world spread across 21 countries , as well as subsidiaries in another seventy. This company is owned by the family of its founder, Antonio Gallardo Carrera, born on June 20, 1908 and who built this empire together with the pharmacist Víctor Almirall Rius, from whom it takes its name.

Until relatively recently, the company was run by the brothers Antonio and Jorge Gallardo Ballart, who gave way to the presidency in May 2022 to the third generation: Carlos Gallardo Piqué, son of Jorge Gallardo .

Piqué, who graduated in industrial engineering from the Polytechnic University of Catalonia (UPC), has extensive experience as an executive in companies such as Pfizer , as well as in the company run by his father. Before heading Almirall, Carlos Piqué assumed the general management of the pharmaceutical company’s subsidiary in Ireland and the United Kingdom.

In 2014, Piqué founded CG Ventures with the aim of investing in technology companies in the health sector, a task very much in line with the agreement signed with Microsoft.

__

(Featured image by efes via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us